DexCom Earnings Call Highlights Margin Rebound, Growth

Dexcom ((DXCM)) has held its Q4 earnings call. Read on for the main highlights of the call.

Valentine's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

DexCom’s latest earnings call struck a decidedly upbeat tone, underscoring a strong operational recovery after earlier supply issues. Management highlighted double‑digit revenue growth, expanding margins, and powerful cash generation, arguing that new products and manufacturing efficiencies position the company for sustained profitable growth despite manageable near‑term headwinds.

Revenue Growth Reaccelerates in U.S. and Abroad

DexCom reported worldwide revenue of $1.26 billion versus $1.11 billion a year earlier, marking 13% reported growth and 12% organic. U.S. Q4 revenue climbed 11% year over year to $892 million, while international revenue jumped 18% to $368 million, or 15% on an organic basis, signaling broad‑based demand.

Gross Margin Rebound Shows Operational Repair

Gross profit reached $799.8 million in Q4, equal to 63.5% of revenue and up roughly 410 basis points from the prior year. Management credited more than 200 basis points of sequential margin improvement to rebuilt inventory, restored ocean freight usage, and lower scrap rates after earlier deployment missteps.

Profitability Strength and Cash Pile Grow

Operating income came in at $331.5 million, 26.3% of revenue, while adjusted EBITDA was $422.2 million, or 33.5%, modestly below last year’s 27% margin but still robust. Net income was $265.1 million, or $0.68 per share, and free cash flow topped $1 billion for the first time, leaving DexCom with about $2.0 billion in cash and equivalents.

G7 15‑Day Sensor Positioned as Margin Catalyst

The broad U.S. rollout of the G7 15‑day system is now complete across all channels, with early user feedback emphasizing longer wear and better accuracy. Management calls it the most accurate sensor the company has produced and expects the 15‑day format to provide a structural tailwind to gross margin over time.

New Features and Clinical Tools Expand Ecosystem

DexCom is launching Smart Basal in early access this month, targeting type 2 patients on basal insulin and broadening its addressable market. The company is also ramping Direct EHR integration at more than 160 health systems, enhancing clinical workflow, while planning Stelo app upgrades and deploying a newly cleared patch aimed at improving sensor survival.

International Growth Accelerates with Type 2 Tailwinds

International organic revenue grew 15% in Q4, led by strong performances in Germany, the U.K. and France. France was singled out as one of the fastest‑growing markets thanks to expanded access for type 2 patients, and management sees significant further upside from new product introductions across non‑U.S. markets.

Capital Allocation Balances Deleveraging and Buybacks

DexCom used its ample liquidity to settle $1.2 billion of expiring convertible notes entirely in cash, simplifying its capital structure. It also repurchased $300 million of stock in the open market during the quarter, all while maintaining its approximate $2.0 billion cash position for flexibility.

Stelo Adds Growth and a Future Patient Funnel

The Stelo consumer wellness offering generated about $130 million of revenue in 2025, landing at the high end of its previously guided growth contribution. Management expects Stelo to add roughly one percentage point to 2026 revenue growth and sees it as both a standalone business and a funnel into reimbursed CGM as coverage broadens.

Earlier Supply and Deployment Issues Linger in the Numbers

Executives were candid that earlier 2025 sensor deployment and supply challenges weighed on results, notably via higher warranty, scrap and freight costs. While Q4 showed meaningful improvement after remediation efforts, management emphasized that these disruptions left a visible mark on parts of 2025 performance.

Manufacturing Ramp in Ireland to Lift Costs Near Term

DexCom outlined plans to staff and validate a new manufacturing facility in Ireland, expected to come online late 2026. These ramp‑up investments will push operating expenses higher and temporarily pressure the profit and loss statement until the site is fully utilized and its costs migrate into cost of goods sold.

Seasonal Q1 Sets Uneven Revenue Cadence

Management warned investors to expect a sequential revenue decline of roughly 6% to 7% from Q4 into Q1, reflecting normal seasonality. This means quarterly cadence will be uneven, with a softer first quarter despite the underlying growth story remaining intact for the full year.

Medicare Coverage Timeline and Structure Still Cloudy

The company remains optimistic about expanding Medicare coverage to type 2 non‑insulin users, with clinical data expected mid‑year. However, the exact timing and design of any coverage changes, including potential competitive processes, remain uncertain and could influence pricing and the pace at which new lives are added.

Competition and Pricing Continue as Background Risks

DexCom acknowledged ongoing competitive pressure, including from large incumbents with extensive international reach and rival CGM offerings. Payer negotiations, involving pharmacy benefit managers and public programs, create continuing pricing and mix risks, though management expects current rebate dynamics to stay broadly stable for G7 15‑day.

International Expansion Opportunity Comes with Long Timelines

While management sees a large international runway, they cautioned that meaningful rebalancing of revenue toward overseas markets will take many years. In several scenarios the full potential stretches beyond a five‑year horizon, putting the emphasis on disciplined, long‑term execution rather than quick wins.

Guidance Signals Confident but Disciplined Outlook

For 2026, DexCom guided revenue to $5.16 billion to $5.25 billion, implying 11% to 13% growth, with non‑GAAP gross margin of 63% to 64% and operating margin around 22% to 23%. The company targets adjusted EBITDA margins of 30% to 31% and expects 200 to 300 basis points of gross margin expansion driven by lower freight, manufacturing efficiencies, G7 15‑day and incremental Stelo and product contributions.

DexCom’s earnings call painted a picture of a company exiting a choppy supply year with stronger fundamentals and a richer product pipeline. While near‑term cost ramps, seasonality and reimbursement unknowns remain, management’s confidence in sustained double‑digit growth and expanding profitability suggests the CGM leader still sees substantial runway ahead.

Disclaimer & DisclosureReport an Issue